SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-107031
Filing Date
2024-09-17
Accepted
2024-09-17 09:00:08
Documents
17
Period of Report
2024-09-15
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atha-20240915.htm   iXBRL 8-K 61524
2 EX-10.1 atha-ex10_1.htm EX-10.1 27381
3 EX-10.2 atha-ex10_2.htm EX-10.2 93436
4 EX-99.1 atha-ex99_1.htm EX-99.1 21722
5 GRAPHIC img60298552_0.jpg GRAPHIC 38610
6 GRAPHIC img60298552_1.jpg GRAPHIC 38610
7 GRAPHIC img247042425_0.jpg GRAPHIC 17633
  Complete submission text file 0000950170-24-107031.txt   485393

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atha-20240915.xsd EX-101.SCH 26990
19 EXTRACTED XBRL INSTANCE DOCUMENT atha-20240915_htm.xml XML 4888
Mailing Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011
Business Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011 (425) 620-8501
Athira Pharma, Inc. (Filer) CIK: 0001620463 (see all company filings)

IRS No.: 453368487 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39503 | Film No.: 241302692
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)